KZR - Kezar Life Sciences, Inc Forecast Levels Chart
The price action of Kezar Life Sciences (KZR) reflects the impact of stringent FDA oversight and capital-intensive research, where patent protection for Sec61 inhibitors limits competition. Kezar Life Sciences is implementing advanced immunology by reprogramming the body's defenses to combat autoimmune pathologies. The current metric stands at 6.97, while management optimizes costs and adjusts the project portfolio in anticipation of key test results.
%20Price%20Target%20Chart&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_KZR_-_Kezar-Life-Sciences_-_Price-Target-Chart "Fair Value Consensus: Kezar Life Sciences (KZR) for 07/04/2022 - 05/23/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Kezar Life Sciences, Inc (KZR)
- stock value and consensus price forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Kezar Life Sciences|KZR - Long-Term Debt to Capital|Short-Term Debt to Capital Kezar Life Sciences Inc|KZR - Company Debts|Debt to Net Assets Ratio Kezar Life Sciences, Inc|KZR - Company Long-Term Debt|Company Current Liabilities Kezar Life Sciences|Quick Ratio kezarlifesciences.com
- earnings and valuation multiples information:
KZR - Net Income|Expected Net Income Kezar Life Sciences|KZR - P/E Multiple|Market Cap to Projected Earnings Kezar Life Sciences Inc.|KZR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Kezar Life Sciences, Inc|KZR - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Kezar Life Sciences|KZR - Net earnings per share for the last 12 months|Quarterly EPS earnings growth kezarlifesciences.com|KZR - Earnings per share growth in current year|Projected earnings per share growth rate for next year Kezar Life Sciences
Fundamental company analysis:kezarlifesciences.com, KZR
A conservative investor views the fundamental value of Kezar Life Sciences (KZR) through the lens of future insurance reimbursements for innovative autoimmune pathology therapies. The consensus target price aggregates weighted average expert forecasts for the year, transforming fragmented capitalization expectations into a single vector, which allows for an assessment of the assets' growth potential relative to current market quotes.
Competitors of Kezar Life Sciences
Analyst Consensus Forecast argenx.com (ARGX)|BioNTech - Consensus Target|ABVX (Abivax SA) - Forecast Levels Chart|ADMA - Price Target Chart|Fair Value Consensus PTGX (Protagonist Corp)|Immunovant, Inc. (IMVT) - Price Target Chart|Forecast Levels Chart KNSA (kiniksa.com)|GRFS (Grifols) - Analyst Consensus Forecast|ADPT: Fair Value Consensus|Analyst Consensus Forecast CLDX|Analyst Consensus Forecast Aurinia Corp (AUPH)|Price Target Chart BioCryst BCRX|Fair Value Consensus VERA|DNTH - Price Target Chart|Pharvaris NV (PHVS) - Consensus Target|ABCL: Analyst Consensus Forecast|Tourmaline (TRML) - Analyst Consensus Forecast|Consensus Target PGEN|PHAR: Fair Value Consensus|Analyst Consensus Forecast NKTR|Analyst Median Target Upstream Bio, Inc.|Price Target Chart Zenas Biopharma, Inc. ZBIO|IMNM - Consensus Target|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|SEPN (Septerna) - Consensus Target|Pieris Pharma (PVLA) - Analyst Consensus Forecast|Price Target Chart Savara Corp|Broker Consensus Forecast RIGL (Rigel Corp)|Analyst Consensus Forecast ANAB|ATXS - Average Forecast Price|Price Target Chart enGene ENGN|Analyst Consensus Forecast rapt.com RAPT|Aerovate - Analyst Consensus Forecast|Average Forecast Price Aclaris Therapeutics, Inc|KYTX (Kyverna Therapeutics) - Consensus Target|Forecast Levels Chart TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Ventyx Biosciences Inc.|Price Target Chart Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Fair Value Consensus|Eledon Pharmaceuticals - Consensus Target|Fair Value Consensus AGEN|CLYM - Price Target Chart|ZURA: Price Target Chart|ATYR: Analyst Consensus Forecast|ADAG - Analyst Median Target|IMA (ImageneBio) - Analyst Consensus Forecast|Shattuck Therapeutics - Forecast Levels Chart|Analyst Consensus Forecast EQ|CNTB - Average Forecast Price|Immunic - Consensus Target|Fair Value Consensus ATRA|IFRX - Price Target Chart|Analyst Median Target x4pharma.com XFOR|ACET: Analyst Consensus Forecast|Consensus Target Celularity|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Barinthus Biotherapeutics Corp (BRNS) - Analyst Median Target|Analyst Consensus Forecast SABS|AKTX - Average Forecast Price|Price Target Chart Enlivex Therapeutics Ltd. ENLV|QTTB: Broker Consensus Forecast|GeoVax Labs Inc - Analyst Consensus Forecast|Edesa Biotech Corp (EDSA) - Consensus Target|IBIO: Analyst Consensus Forecast|Average Forecast Price Carisma Therapeutics Inc. (CARM)|Price Target Chart XTL Biopharmaceuticals Ltd.|Bolt Bio (BOLT) - Analyst Median Target|Price Target Chart HCW Biologics Inc. (HCWB)|Analyst Consensus Forecast aptevotherapeutics.com (APVO)|AIM ImmunoTech - Consensus Target|ADTX (Aditxt Inc.) - Forecast Levels Chart|GRI - Price Target Chart|Fair Value Consensus XRTX (XORTX Therapeutics Inc)|ReShape Lifesciences (HIND) - Price Target Chart|Forecast Levels Chart REVB (Revelation Biosciences Corp)|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|SCNI: Fair Value Consensus|Analyst Consensus Forecast CALI|Analyst Consensus Forecast affimed.com (AFMD)|Price Target Chart Allakos ALLK|Fair Value Consensus HOOK|IGMS - Price Target Chart|iteostherapeutics.com (ITOS) - Consensus Target|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Consensus Target THRD
